Engagement at Investor Conferences
Opus Genetics, Inc. (NASDAQ: IRD), a clinical-stage biopharmaceutical company, is gearing up for key investor conferences where its management team will engage with investors. This opportunity illustrates their commitment to transparency and collaboration within the biopharmaceutical space. Their focus on innovative solutions to restore vision for individuals suffering from inherited retinal diseases is central to their mission.
Upcoming Conference Participation
The schedule includes participation in the BTIG 5th Annual Ophthalmology Day, a virtual event where Dr. Ash Jayagopal, Chief Scientific and Development Officer, will partake in a fireside chat. This session is set to take place on a Monday afternoon, providing insights into the company’s progress and future plans.
Another Key Event at Piper Sandler Conference
Additionally, George Magrath, M.D., the Chief Executive Officer, will be present at the Piper Sandler 37th Annual Healthcare Conference in New York. This meeting is a chance for attendees to learn more about Opus Genetics' innovative approaches to treating inherited retinal diseases. Such platforms are essential for fostering relationships in the investment community.
Focus on Innovative Gene Therapies
Opus Genetics continues to develop groundbreaking gene therapies aimed at addressing the root causes of inherited retinal diseases. The company acknowledges the significant impact that severe retinal disorders can have on patients' lives and is dedicated to creating durable, one-time treatment solutions.
Detailed Pipeline Overview
With a robust pipeline featuring an array of AAV-based programs, Opus Genetics is leading the charge in treating conditions linked to LCA5 mutations, BEST1-related retinal degeneration, and more. Key candidates, such as OPGx-LCA5 and OPGx-BEST1, are in advanced stages of development, demonstrating the company's commitment to advanced biopharmaceutical innovation.
Additional Pharmaceutical Advances
In addition to gene therapies, Opus Genetics is also promoting Phentolamine Ophthalmic Solution 0.75%. This is a small-molecule therapy that has gained approval for treating pharmacologically induced mydriasis, alongside prospective applications for conditions such as presbyopia and low-light visual disturbances following keratorefractive surgery. Such advancements showcase the company’s comprehensive approach to ocular therapeutics.
Company Background
Located in Research Triangle Park, Opus Genetics has positioned itself at the forefront of biopharmaceutical innovation. Their unique approach is designed not only to treat symptoms but also to tackle the genetic roots of retinal diseases, an area that has seen significant evolution and demand over the years.
Contact Information for Inquiries
For investors seeking further information about the company’s strategic initiatives and developments, key contacts have been provided:
Investors:
Jenny Kobin
Remy Bernarda
Contact through email for inquiries.
Frequently Asked Questions
What is Opus Genetics focused on?
Opus Genetics specializes in developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases.
When are the key investor conferences?
The company will participate in investor conferences on December 1 and 2, 2025, featuring key management personnel.
What therapies are currently under development?
The company is developing several AAV-based gene therapies, including those targeting LCA5 and BEST1-related retinal degenerative conditions.
Where is Opus Genetics located?
Opus Genetics is headquartered in Research Triangle Park, NC.
How can investors reach out for more information?
Investors can reach out via contact details provided on the company's official channels for any inquiries related to investments.
